HELP on Nasdaq

Helus Pharma Inc.

Helus Pharma Inc. is a Canadian pharmaceutical preparations company based in Toronto.1 Its shares trade on Nasdaq under the symbol HELP.1

Price unavailable

Last updated Oct 20, 2026.

Overview

-113.1MNet income, fiscal 20252

Compare with Quantum Biopharma Ltd., Adastra Holdings Ltd. or PyroGenesis Canada Inc., or pick any stock.

  • TickerHELP on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersA11
  • Incorporated inBritish Columbia, Canada3
  • Business address100 King Street West, Suite 5600, Toronto3
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in CAD, the currency the company reports in.

Key numbers, fiscal 2022

-100.0%Revenue growth, 20224
-88.8%Return on equity5
-45.3M CADFree cash flow6

Financial statements

Revenue40 CAD in 2022
0250.0K CAD500.0K CAD750.0K CAD1.0M CAD2021: 864.0K CAD864.0K CAD20212022: 0 CAD0 CAD2022
Gross profit40 CAD in 2022
050.0K CAD100.0K CAD150.0K CAD200.0K CAD2021: 200.0K CAD200.0K CAD20212022: 0 CAD0 CAD2022
Net income46-67.6M CAD in 2022+110% since 2021
-80.0M CAD-60.0M CAD-40.0M CAD-20.0M CAD02021: -32.2M CAD-32.2M CAD20212022: -67.6M CAD-67.6M CAD2022+110%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2026-03-312025-03-31
Research$86.6M$39.2M
General and administrative costs$45.1M$32.6M
Share-based compensation$10.9M$31.3M
TOTAL EXPENSES$142.6M$103.1M
Interest income$5.1M$6.0M
Foreign currency translation gain$492.0K$15.5M
Other loss-$2.6M-$20.0K
Debt issuance cost-$2.9M$0
Fair value loss on financial instruments-$5.5M$0
TOTAL OTHER INCOME (LOSS)-$5.4M$21.5M
NET LOSS FOR THE YEAR-$148.0M-$81.6M
Unrealized gain (loss) on translation of foreign operations$188.0K-$14.4M
COMPREHENSIVE LOSS FOR THE YEAR-$147.8M-$96.0M
Basic loss per share for the year (in dollars per share)-$4.25-$4.04
Diluted loss per share for the year (in dollars per share)-$4.25-$4.04
Weighted average number of common shares outstanding - diluted (in shares)34.8M shares20.2M shares
Weighted average number of common shares outstanding - basic (in shares)34.8M shares20.2M shares

Compare Helus Pharma Inc. with another company

Corporate structure

Helus Pharma Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Helus Pharma Inc.

  • Eric H. L. So Filed SCHEDULE 13D on Helus Pharma Inc., latest Sep 9, 2026
  • Paul Glavine Filed SCHEDULE 13D on Helus Pharma Inc., latest Sep 9, 2026
  • Sirenia Capital Management LP Filed SCHEDULE 13G/A on Helus Pharma Inc., latest Aug 14, 2026 (2 filings since May 15, 2026)
  • Adage Capital Management, L.P. Filed SCHEDULE 13G on Helus Pharma Inc., latest Aug 12, 2026
  • Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Helus Pharma Inc., latest May 15, 2026 (7 filings since Sep 15, 2023)
  • MILLENNIUM MANAGEMENT LLC Filed SCHEDULE 13G/A on Helus Pharma Inc., latest Apr 22, 2026 (3 filings since Mar 26, 2026)
  • ORBIMED ADVISORS LLC Filed SCHEDULE 13G on Helus Pharma Inc., latest Feb 17, 2026
  • TANG CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Helus Pharma Inc., latest Feb 17, 2026 (4 filings since Dec 3, 2024)
  • Deep Track Capital, LP Filed SCHEDULE 13G/A on Helus Pharma Inc., latest Feb 13, 2026 (4 filings since Mar 22, 2024)
  • Venrock Healthcare Capital Partners III, L.P. Filed SCHEDULE 13G on Helus Pharma Inc., latest Nov 7, 2025
  • RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Helus Pharma Inc., latest Feb 14, 2025 (2 filings since Mar 25, 2024)
  • Logos Global Management LP Filed SC 13G/A on Helus Pharma Inc., latest Nov 14, 2024 (2 filings since Aug 27, 2024)
  • Helus Pharma Inc. A1

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Helus Pharma Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net141.0K CAD2 Mar 31, 2025266.0K CAD2 Mar 31, 2024−47.0%
Operating-lease assets (leased space)0 CAD2 Mar 31, 2025281.0K CAD2 Mar 31, 2024−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents135.0M CAD2 Mar 31, 2025209.0M CAD2 Mar 31, 2024−35.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill51.5M CAD2 Mar 31, 202547.5M CAD2 Mar 31, 2024+8.5%
Intangible assets, net (excluding goodwill)41.0M CAD2 Mar 31, 202535.5M CAD2 Mar 31, 2024+15.7%

Leadership

Who has led Helus Pharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Halstead2026–now
Board members and other officers (1)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerAaron Bartlone named Jul 10, 2023 to Sep 1, 202610
  • Executive OfficerAlex Nivorozhkin named Mar 21, 2022 to Sep 1, 202610
  • Executive OfficerAmir Inamdar named Jul 16, 2026 to Sep 1, 202610
  • Executive Officer, DirectorEric So named Mar 21, 2022 to Sep 1, 202610
  • Executive OfficerGabriel Fahel named Jul 10, 2023 to Sep 1, 202610
  • Executive OfficerGeorge Tziras named Apr 3, 2024 to Sep 1, 202610
  • Executive OfficerGreg Cavers named Mar 21, 2022 to Sep 1, 202610
  • Executive OfficerMichael Cola named Mar 23, 202611
  • Executive OfficerDouglas Drysdale named Apr 3, 2024 to Aug 27, 202512
  • Director, Executive OfficerDoug Drysdale named Mar 21, 2022 to Nov 29, 202313
  • Executive OfficerBrett Greene named Apr 28, 202214
  • Executive OfficerGabe Fahel named Mar 21, 2022 to Apr 28, 202214
  • Executive OfficerLori Challenger named Mar 21, 2022 to Apr 28, 202214
  • Executive OfficerMichael Palfreyman named Mar 21, 2022 to Apr 28, 202214
  • Executive OfficerBrett Green named Mar 21, 2022 to Mar 22, 202215
  • DirectorEric Hoskins named Mar 21, 2022 to Sep 1, 202610
  • DirectorFreda Lewis-Hall named Jul 16, 2026 to Sep 1, 202610
  • DirectorGrant Froese named Mar 21, 2022 to Sep 1, 202610
  • DirectorMark Lawson named Mar 21, 2022 to Sep 1, 202610
  • DirectorTheresa Firestone named Mar 21, 2022 to Sep 1, 202610

Former names

  • CYBIN INC.Nov 20, 2020 to Sep 23, 20263

Timeline

  1. Sep 17, 2026New chief executive Michael Halstead becomes CEO8

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.39) a share, on Nov 13, 2025.16

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

423 filings to the SEC since October 2021: 6 annual reports, 15 insider forms, 33 large holders, 23 private raises, 346 other. The latest 20:

  1. Oct 15, 20266-K EDGAR
  2. Oct 8, 20266-K EDGAR
  3. Oct 5, 20266-K EDGAR
  4. Oct 2, 20266-K EDGAR
  5. Oct 1, 20266-K EDGAR
  6. Oct 1, 20264 EDGAR
  7. Oct 1, 20264 EDGAR
  8. Oct 1, 20263 EDGAR
  9. Oct 1, 20264 EDGAR
  10. Sep 23, 20266-K EDGAR
  11. Sep 22, 20266-K EDGAR
  12. Sep 21, 20266-K EDGAR
  13. Sep 21, 20264 EDGAR
  14. Sep 17, 20263 EDGAR
  15. Sep 11, 20264 EDGAR
  16. Sep 11, 20264 EDGAR
  17. Sep 11, 20264 EDGAR
  18. Sep 10, 20266-K EDGAR
  19. Sep 10, 20264 EDGAR
  20. Sep 10, 20264 EDGAR

The 423 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 21, 2026Halstead MichaelChief Executive OfficerBuy100,000$13.47$1.3MForm 4
Sep 8, 2026Glavine PaulChief Growth OfficerBuy100,000$12.47$1.2MForm 4
Sep 8, 2026Glavine PaulChief Growth OfficerBuy100,000$12.47$1.2MForm 4
Sep 8, 2026So Eric H. L.Executive ChairBuy100,000$12.39$1.2MForm 4
Sep 4, 2026So Eric H. L.Executive ChairBuy100,000$12.09$1.2MForm 4
Sep 3, 2026Glavine PaulChief Growth OfficerBuy100,000$11.78$1.2MForm 4
Sep 1, 2026So Eric H. L.Executive ChairBuy95,000$11.81$1.1MForm 4
Aug 31, 2026Glavine PaulChief Growth OfficerBuy90,000$11.59$1.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 19, 2026Filed a private offering of securities Form D: $261,987 offered in all Form D
  2. Aug 3, 2026Filed a private offering of securities Form D: 1 investor so far Form D
  3. Aug 3, 2026Filed a private offering of securities Form D: 2 investors so far Form D
  4. Jul 1, 2026Filed a private offering of securities Form D: 5 investors so far Form D
  5. Jul 1, 2026Filed a private offering of securities Form D: $511,720 offered in all Form D
  6. Mar 10, 2026Filed a private offering of securities Form D: 1 investor so far Form D
  7. Dec 31, 2025Filed a private offering of securities Form D: $114,154 offered in all Form D
  8. Nov 14, 2025Filed a private offering of securities Form D: $288,580 offered in all Form D
  9. Oct 1, 2025Filed a private offering of securities Form D: $601,865 offered in all Form D
  10. Aug 29, 2025Filed a private offering of securities Form D: $120,070 offered in all Form D
  11. Aug 15, 2025Filed a private offering of securities Form D: $637,404 offered in all Form D
  12. Aug 15, 2025Filed a private offering of securities Form D: $288,280 offered in all Form D
  13. Jun 30, 2025Raised $50 million in a private offering of debt Form D: 1 investor so far Form D
  14. Nov 27, 2024Filed a private offering of securities Form D: $748,395 offered in all Form D
  15. Aug 15, 2024Filed a private offering of securities Form D: $3.2 million offered in all Form D
  16. Apr 5, 2024Filed a private offering of securities Form D: $1.9 million offered in all Form D
  17. Mar 19, 2024Raised $108.7 million in a private offering of equity Form D: 12 investors so far Form D
  18. Nov 16, 2023Filed a private offering of securities Form D: $1.7 million offered in all Form D
  19. Jun 29, 2023Filed a private offering of securities Form D: $2 million offered in all Form D
  20. Mar 8, 2022Raised $317,098 in a private offering of securities Form D: 1 investor so far Form D
  21. Mar 4, 2022Raised $17,725 in a private offering of securities Form D: 1 investor so far Form D
  22. Dec 14, 2020Raised $342,513 in a private offering of securities Form D: 5 investors so far Form D
  23. Nov 27, 2020Raised $2.9 million in a private offering of securities Form D: 9 investors so far Form D

SEC filer profile

How Helus Pharma Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHelus Pharma Inc.1
  • CIK0001833141
  • Filer status<br>emerging growth company an emerging growth company1
  • Incorporated inOntario31
  • Fiscal year endsMarch 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address100 King Street West, Suite 5600, Toronto, Ontario, Canada1
  • Phone(908) 764-83851
  • Shares outstanding51,631,804 shares as of Mar 31, 202631
  • On EDGAR sinceNov 20, 20201
  • Filings442 in all: 6-K (301), D (27), SUPPL (19), 4 (11), SCHEDULE 13G/A (11), 6-K/A (10), SCHEDULE 13G (8), F-X (7)1
    All 26 form types

    SC 13G (7), F-10 (6), 40-F (5), SC 13G/A (5), 3 (4), FWP (4), EFFECT (3), CERT (2), F-10/A (2), SCHEDULE 13D (2), 25 (1), 40-F/A (1), 40FR12B (1), 8-A12B (1), CORRESP (1), F-10POS (1), S-8 (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (40-F) Jun 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Shares, no par valueHELPThe Nasdaq Stock Market LLC

From the cover page of the 40-F filed Jun 29, 2026 (Section 12(b) of the Exchange Act).31

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31